



## Red blood cell distribution width is a predictive factor of anthracycline-induced cardiotoxicity

メタデータ	言語: English 出版者: 公開日: 2022-05-24 キーワード (Ja): キーワード (En): 作成者: 八重樫, 大輝 メールアドレス: 所属:
URL	<a href="https://fmu.repo.nii.ac.jp/records/2000390">https://fmu.repo.nii.ac.jp/records/2000390</a>

# 学 位 論 文

Red blood cell distribution width is a predictive factor of  
anthracycline-induced cardiotoxicity

(赤血球分布幅はアントラサイクリンによる心毒性の予測因子となる)

福島県立医科大学大学院 医学研究科

循環病態学 循環器内科学講座

八重樫 大輝



## 論文内容要旨

しめい 氏名	やえがし だいき 八重樫 大輝
学位論文題名	Red blood cell distribution width is a predictive factor of anthracycline-induced cardiotoxicity (赤血球分布幅はアントラサイクリンによる心毒性の予測因子となる)
<p>赤血球の大きさのばらつきを示す赤血球分布幅 (red blood cell distribution width : RDW) は循環器疾患の予後と関連していることが報告されている。しかし、がん治療関連心筋障害 (cancer therapeutics-related cardiac dysfunction : CTRCD) の発症との関係については検討されていなかった。今回我々は化学療法が施行される前の RDW がアントラサイクリンによる CTRCD の発症を予測できるかを検討した。</p> <p>アントラサイクリン投与を予定している 202 名のがん患者を登録し 12 か月間の追跡調査を行った。患者を化学療法前の RDW の中央値により 2 群に分けた (低 RDW 群 : n=98, 13.0 [12.6~13.2] , 高 RDW 群 : n=104, 14.9 [13.9~17.0] ) 。心エコー検査を化学療法前と化学療法から 3 か月後、6 か月後、12 か月後に経時的に施行し心機能を評価した。化学療法前の左室収縮末期容積指数および左室駆出率 (EF) は両群間で同等であった。化学療法後は高 RDW 群では 3 か月後および 6 か月後に EF が有意に低下したが (化学療法前 : 64.5%[61.9-68.9%], 3 か月後 : 62.6%[60.4-66.9%], 6 か月後 : 63.9%[60.0-67.9%], 12 か月後 : 64.7%[60.8-67.0%], P = 0.04) 、低 RDW 群では変化は認めなかった。さらに CTRCD の発生率は、高 RDW 群が低 RDW 群よりも有意に高かった (11.5% vs. 2.0%, P = 0.008) 。RDW のカットオフ値を 13.8 とした場合、CTRCD 発症を予測する感度と特異度はそれぞれ 84.6%と 62.0%であった。多変量ロジスティック回帰分析では化学療法前の RDW が CTRCD 発症の独立した予測因子であることが明らかとなった (オッズ比 1.390, 95% confidence interval 1.09-1.78, P=0.008) 。さらに累積アントラサイクリン投与量、EF、アルブミン、高血圧の有無などの既知の危険因子を含む回帰モデルに RDW を加えると、CTRCD を予測するための回帰モデルがより精度の高いものになることが、net reclassification index と integrated discrimination improvement の統計解析によって示された。</p> <p>結論として化学療法前の RDW はアントラサイクリン系薬剤による CTRCD 発症を予測する新しいパラメータになることが示された。</p>	



Red blood cell distribution width is a predictive factor of  
anthracycline-induced cardiotoxicity

Daiki Yaegashi, MD

Department of Cardiovascular Medicine, Fukushima Medical University

## **Abstract**

**Background:** Red blood cell distribution width (RDW) is associated with prognosis in widespread cardiovascular fields, but little is known about relationship with the onset of cancer therapeutics-related cardiac dysfunction (CTRCD).

**Objectives:** The purpose of this study was to assess whether RDW could predict the onset of CTRCD by anthracycline.

**Methods:** Consequential 202 cancer patients planned for anthracycline treatment were enrolled and followed up for 12 months. The patients were divided into 2 groups based on the median value of baseline RDW before chemotherapy (low RDW group, n=98, 13.0 [12.6-13.2]; high RDW group, n=104, 14.9 [13.9-17.0]). Cardiac function was assessed serially by echocardiography at baseline (before chemotherapy), as well as at 3 months, 6 months and 12 months after chemotherapy with anthracycline.

**Results:** Baseline left ventricular end systolic volume index and ejection fraction (EF) were similar between two groups. After chemotherapy, EF decreased at 3-month and 6-month in the high RDW group (baseline, 64.5% [61.9%-68.9%]; 3-month, 62.6% [60.4%-66.9%]; 6-month, 63.9% [60.0%-67.9%]; 12-month, 64.7% [60.8%-67.0%], P=0.04), but no change was observed in low RDW group. The occurrence of CTRCD was higher in high RDW group than in low RDW group (11.5% vs. 2.0%,

P=0.008). When we set the cut-off value of RDW at 13.8, sensitivity and specificity to predict CTRCD were 84.6% and 62.0%, respectively. Multivariable logistic regression analysis revealed that baseline RDW value was an independent predictor of the development of CTRCD (odds ratio 1.390, 95% CI [1.09-1.78], P=0.008). The value of net reclassification index (NRI) and integrated discrimination improvement (IDI) for detecting CTRCD reached statistical significance when baseline RDW value was added to the regression model including known risk factors such as cumulative anthracycline dose, EF, albumin, and the presence of hypertension; 0.9252 (95%CI 0.4103-1.4402, P<0.001) for NRI and 0.1125 (95%CI 0.0078-0.2171, P=0.035) for IDI.

**Conclusions:** Baseline RDW is a novel parameter to predict anthracycline-induced CTRCD.

**Keywords:** Cardio-Oncology, Anthracycline, Red blood cell distribution width, Cancer therapeutics-related cardiac dysfunction, Heart failure.



## **Introduction**

Anthracycline-containing chemotherapy is highly effective and widely used in cancer treatments.

However, anthracycline-induced cardiotoxicity is associated with a poor prognosis in cancer survivors, and the frequency of onset depends on risk factors including cumulative dose of anthracycline, elderly or pediatric population, concomitant or previous radiation therapy, pre-existing cardiovascular diseases, and concomitant use of human epidermal growth factor receptor 2 (HER2) inhibitors[1]. Several hypotheses have been proposed for the mechanisms of anthracycline-induced cardiotoxicity, such as oxidative stress, iron accumulation in myocardial cells, mitochondrial dysfunction, and topoisomerase 2 $\beta$  dysfunction[2-5]. Most anthracycline-induced cardiotoxicity occurs within the first year of chemotherapy, and early detection and treatment may recover cardiac function[6]. Therefore, assessment of cardiac function should be performed to detect early phase of cardiotoxicity, and accurate predictors are required to identify patients predisposed to anthracycline-induced cardiotoxicity.

Red blood cell distribution width (RDW) is a simple and rapid measurement of the heterogeneity of erythrocyte volume. Growing body of evidence suggests that high RDW is strongly associated with poor prognosis in widespread cardiovascular diseases such as acute coronary syndrome, heart failure, and pulmonary hypertension[7-9]. However, the association between anthracycline-induced cardiotoxicity and RDW have not been rigorously examined. The purpose of the present study

was to assess whether baseline RDW could predict the onset of cancer therapeutics-related cardiac dysfunction (CTRCD) by anthracycline-containing chemotherapy.

## **Methods**

### **Study subjects and protocol**

We enrolled 234 consecutive cancer patients, planned for initial anthracycline-containing chemotherapy at Fukushima Medical University hospital from February 2017 to September 2019 (Figure 1). Patients were excluded if they were died or transferred to other hospitals within 12 months follow-up period (n = 32). Remaining 202 patients were divided into 2 groups based on the median value of RDW (13.6) before chemotherapy: low RDW group, n=98, 13.0 [12.6-13.2] and high RDW group, n=104, 14.9 [13.9-17.0].

Hypertension was defined as a history of use of antihypertensive drug or systolic blood pressure of  $\geq 140$  mmHg, and/or diastolic blood pressure  $\geq 90$  mmHg. Diabetes was defined as a recent use of insulin treatment or hypoglycemic drug, or hemoglobin A1c  $\geq 6.5\%$ . Dyslipidemia was defined as a history of use of cholesterol-lowering drugs, or triglyceride was  $\geq 150$  mg/dl, low density lipoprotein cholesterol was  $\geq 140$  mg / dl, and/or high-density lipoprotein cholesterol was  $\leq 40$  mg/dl. Cumulative dose of anthracycline was expressed as a doxorubicin equivalent[1]. HER 2 inhibitor included

trastuzumab and pertuzumab. Radiation therapy was defined as irradiation to the mediastinum.

Transthoracic echocardiography and blood sampling test were performed at baseline, as well as at 3 months, 6 months, and 12 months after administration of anthracyclines. All procedures used in this research were approved by the Ethical Committee of Fukushima Medical University Hospital.

### **Echocardiography**

Transthoracic echocardiography was performed by a trained sonographer, and images were checked by another trained sonographer and an echo-cardiologist. We measured cardiac function using EPIQ 7G (Philips Healthtech, Best, Netherland). EF was calculated using the modified Simpson's method according to the guideline from the American Society of Echocardiography and the European Association of Cardiovascular Imaging [10]. The left ventricular (LV) mass was calculated using the following formula:

$$\begin{aligned} \text{Left ventricular(LV)mass} = & 0.8 \times [1.04 \times \{(\text{LV diastolic diameter} + \\ & \text{interventricular septum wall thickness} + \text{LV posterior wall thickness})^3 - \\ & (\text{LV diastolic diameter})^3\}] + 0.6 \text{ g [10].} \end{aligned}$$

CTRCD was defined as a decrease in EF more than 10% points, to a value less than 53% [11]. LV diastolic dimension index, LV systolic dimension index, LV end-diastolic volume index, LV end-systolic volume index, and left atrial volume index (LAVI) were measured using B-mode ultrasound.

### **Blood sampling**

Blood sampling was performed in a stable condition after an overnight fast. High sensitivity cardiac troponin I (TnI) was measured using an assay based on Luminescent Oxygen Channeling Immunoassay technology, and run on a Dimension EXL integrated chemistry system (Siemens Healthcare Diagnostics, Deerfield, IL, USA). B-type natriuretic peptide (BNP) levels were measured using a specific immunoradiometric assay (Shionoria BNP kit, Shionogi, Osaka, Japan). RDW was measured using a DxH800 (Beckman Coulter, Inc., Fullerton, CA, USA).

### **Statistical analysis**

All statistical analyzes were performed using SPSS version 26 (IBM, Armonk, New York, USA) or R software packages version 3.6.3 (R core team 2020, Vienna, Austria). We used the Shapiro-Wilk test to discriminate which variables were normally or not normally distributed. Normally distributed variables were shown as mean  $\pm$  standard deviation. Non-normally distributed variables were indicated by median

with interquartile range. Category variables were shown in numbers and percentage. Student's t-test was used for variables following a normal distribution, the Mann-Whitney U-test was used for variables of the non-normal distribution, and the  $\chi$ -square test was used for categorical variables. The time course of EF (baseline, 3-month, 6-month, and 12-month after the administration of anthracyclines) was evaluated using the Friedman test.

Logistic regression analysis was performed to identify variables relating to the occurrence of CTRCD. We selected variables as follows: age, sex, hypertension, dyslipidemia, diabetes mellitus, current or past smoker, cumulative anthracycline dose, use of HER2 inhibitor, BNP, albumin, LV mass index, LV end-diastolic volume index, LV end-systolic volume index, EF, LAVI, and RDW. Akaike Information Criteria was used for selecting variables for multivariate analysis. Receiver operator characteristic curve (ROC) analysis was performed to determine the optimal cut-off value of RDW for predicting the occurrence of CTRCD. The improvement by adding RDW to discrimination and net reclassification of risks was assessed by the estimation of both integrated discrimination improvement (IDI) and net reclassification improvement (NRI). The P value of 0.05 or less was defined as significant.

## Results

Table 1 showed patient characteristics at the baseline of chemotherapy. The median value of RDW of all patients before chemotherapy was 13.6, and patients were divided into 2 groups based on the median value. Of 202 patients, 104 patients were grouped as high RDW group (13.6 and above), and 98 patients were grouped as low RDW group (less than 13.6). There were no statistical differences in age, sex, coronary risk factors, cumulative anthracycline dose, the usage of HER2 inhibitor, and radiation therapy between the two groups. High RDW group included lower rate of breast cancer (60.2% vs. 43.2%,  $P=0.016$ ). Laboratory data showed that hemoglobin and mean corpuscular volume were lower in high RDW group, but BNP and TnI levels at baseline were similar between the two groups. The usage of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARB),  $\beta$ -blockers were similar between the two groups. Echocardiographic data demonstrated that LVEDVI, LVMI, and EF at baseline were similar between the two groups. Laboratory data showed similar liver and renal function.

Time-dependent changes in EF are displayed in Figure 2. EF decreased at 3-month and 6-month after chemotherapy in high RDW group (baseline, 64.5% [61.9%-68.9%]; 3-month, 62.6% [60.4%-66.9%]; 6-month, 63.9% [60.0%-67.9%]; 12-month, 64.7% [60.8%-67.0%],  $P=0.04$ , Figure 2B), but no change was observed in low RDW group (Figure 2A). The occurrence of CTRCD during the 12-month

follow-up period was higher in high RDW group than in low RDW group (n=2 [11.5%] vs. n=12 [2.0%] P=0.008). When we set the cut-off value of RDW at 13.8 from the ROC analysis, sensitivity, specificity, and area under the curve to predict CTRCD were 84.6%, 62.0%, and 0.769, respectively, as shown in Figure 3. Multivariable logistic regression analysis revealed that RDW at baseline was an independent predictor of the development of CTRCD (odds ratio 1.390, 95% CI [1.09-1.78], P=0.008; Table 2).

To assess the importance of adding RDW more precisely, NRI and IDI were calculated using the variables with or without RDW. The value of NRI and IDI for detecting CTRCD reached statistical significance when baseline RDW value was added to the model including cumulative dose of anthracycline, EF, albumin and hypertension; 0.9252 (95%CI 0.4103-1.4402, P<0.001) for NRI and 0.1125 (95%CI 0.0078-0.2171, P=0.035) for IDI.

## **Discussion**

In the present study, we revealed the clinical features of RDW in patients treated with anthracycline. First, EF was temporary decreased in high RDW patients. Second, the occurrence of anthracycline-induced CTRCD was significantly higher in high RDW patients. Third, high RDW at baseline was an independent predictor of the development of CTRCD.

Oxidative stress, iron accumulation in myocardial cells, mitochondrial dysfunction, and topoisomerase 2 $\beta$  dysfunction have been proposed as major mechanisms of anthracycline-induced cardiotoxicity [2-5]. The excess production of free radicals by the quinone group from aglycons of anthracycline induces oxidation of protein, nucleic acid, and lipid, leading to cellular damage [4]. It has been reported that elevation of RDW is also associated with oxidative stress as well as aging, inflammation, malnutrition, and renal dysfunction[12, 13]. Among those factors, oxidative stress induces bone marrow dysfunction, leading to abnormal heme synthesis and hemoglobin production that increased in RDW. In the present study, the patients with high RDW at baseline demonstrated time-dependent decrease in EF and higher occurrence of CTRCD. These findings raise the possibility that the patients with high RDW already had been exposed to increased oxidative stress before chemotherapy, and were more vulnerable to additional oxidative stress by anthracycline, resulting in the development of CTRCD.

Although underlying mechanisms of interaction between RDW and CTRCD remains to be elucidated, to the best of our knowledge, this is the first report to demonstrate the association between RDW and CTRCD.

The utility of RDW has been reported in not only cardiovascular disease, but also cancer prognosis. High RDW are associated with unfavorable survival in many types of cancers including



breast cancer[14], hematological tumor[15], gynecological cancer[16, 17], and osteosarcoma[18].

Although there is no clear explanation of the relationship between RDW and cancer prognosis, RDW can be a promising biomarker for assessment of the risk of CTRCD and cancer prognosis. Cardinale et al. reported that 78% patients with anthracycline-induced cardiotoxicity showed a full or partial recovery with heart failure therapy [6]. In this cohort, one patient presented less than 40% of ejection fraction at 6-month follow-up. He was administered  $\beta$ -blockers and ACE inhibitors soon after the onset of CTRCD. Then, his ejection fraction recovered to over 50% at 12-month follow-up. We speculate that early initiation of cardioprotective therapy induced a recovery of cardiac function. Thus, early detection and treatments of CTRCD are essential to minimize cardiac damage induced by anthracyclines. TnI and BNP are widely used surrogate biomarkers to detect CTRCD, but the elevation occurs after starting anthracycline chemotherapy [19]. Compared to them, RDW can predict the development of CTRCD before chemotherapy. By assessing RDW before chemotherapy, precise follow-up management can be scheduled and indication of prophylaxis treatment can be discussed. To date, several clinical studies have demonstrated that angiotensin-converting enzyme and beta-adrenergic receptor blockers prevent cardiac dysfunction after anthracycline chemotherapy [20]. According to previous reports of anti-oxidative effects of carvedilol and ACE inhibitor [21], the efficacy of prophylaxis may be expected to the patients with high RDW.

In the present study, the calculation of NRI and IDI demonstrated the significance of RDW for the prediction of CTRCD. The utility of RDW should be considered when managing cancer patients treated with anthracycline-containing chemotherapy.

### **Limitations**

This study was performed using a relatively small number of patients and short follow-up period by a single center. Longer follow-up and larger population data were needed to confirm the importance of RDW to the development of CTRCD and cardiovascular prognosis. According to 2016 ESC position paper [1], 3 dimensional-based LVEF have advantages to assess cardiac function compared to Simpson's method, and global longitudinal strain reveals subtle changes in left ventricular function, and thus detects myocardial damage in the early stage before reduces in left ventricular ejection fraction [22]. Further studies using 3 dimensional echocardiography and global longitudinal strain are desirable in the future.

### **Conclusion**

Baseline RDW identifies high risk patients with anthracycline-induced CTRCD.

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

### **Author contributions**

Masayoshi Oikawa conceived of the presented idea. Masayoshi Oikawa and Daiki Yaegashi developed the theory and performed the computations. Tetsuro Yokokawa, Tomofumi Misaka, Atsushi Kobayashi, Takashi Kaneshiro, Akiomi Yoshihisa and Kazuhiko Nakazato verified the analytical methods. Yasuchika Takeishi and Takafumi Ishida supervised the findings of this work. All authors discussed the results and contributed to the final manuscript.

### **Funding**

This work was supported by JSPS KAKENHI (Grant Number JP20K08493).

### **Acknowledgement**

The authors thank for Ms. H. Kobayashi for data management.

## References

1. Zamorano JL, Lancellotti P, Munoz DR, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). *Eur Heart J.* (2016) 37:2768-2801. doi:10.1093/eurheartj/ehw211. PubMed PMID: 27567406.
2. Horenstein MS, Vander Heide RS, L'Ecuyer TJ. Molecular basis of anthracycline-induced cardiotoxicity and its prevention. *Mol Genet Metab.* (2000) 71:436-44. doi: 10.1006/mgme.2000.3043. PubMed PMID: 11001837.
3. Link G, Tirosh R, Pinson A, Hershko C. Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction. *J Lab Clin Med.* (1996) 127:272-8. doi: 10.1016/s0022-2143(96)90095-5. PubMed PMID: 9273360.
4. Ichikawa Y, Ghanefar M, Bayeva M, Wu R, Khechaduri A, Naga Prasad SV, et al. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. *J Clin*

Invest. (2014) 124: 617-30. doi: 10.1172/jci72931. PubMed PMID: 24382354; PubMed Central PMCID: PMC3904631.

5. Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. *Nat Med.* (2012) 18:1639-42. doi:10.1038/nm.2919. PubMed PMID: 23104132.
6. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. *Circulation.* (2015) 131:1981-8. doi:10.1161/CIRCULATIONAHA.114.013777. PubMed PMID: 25948538.
7. Abrahan LLt, Ramos JDA, Cunanan EL, Tiongson MDA, Punzalan FER. Red Cell Distribution Width and Mortality in Patients With Acute Coronary Syndrome: A Meta-Analysis on Prognosis. *Cardiol Res.* (2018) 9:144-152. doi:10.14740/cr732w. PubMed PMID: 29904449; PubMed Central PMCID: PMC5997444.
8. Felker GM, Allen LA, Pocock SJ, Shaw LK, McMurray JJ, Pfeffer MA, et al. Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. *J Am Coll Cardiol.* (2007) 50:40-7. doi:10.1016/j.jacc.2007.02.067. PubMed PMID: 17601544.

9. Hampole CV, Mehrotra AK, Thenappan T, Gomberg-Maitland M, Shah SJ. Usefulness of red cell distribution width as a prognostic marker in pulmonary hypertension. *Am J Cardiol.* (2009) 104:868-72. doi:10.1016/j.amjcard.2009.05.016. PubMed PMID: 19733726.
10. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr.* (2015) 28: 1-39.e14. doi:10.1016/j.echo.2014.10.003. PubMed PMID: 25559473.
11. Plana JC, Gaiderisi M, Barac A, Ewer MS, Bonnie Ky, Scherrer-Crosbie M, et al. Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr.* (2014) 27: 911-39. doi: 10.1016/j.echo.2014.07.012. PubMed PMID: 25172399.
12. Salvagno GL, Sanchis-Gomar F, Picanza A, Lippi G. Red blood cell distribution width: A simple parameter with multiple clinical applications. *Crit Rev Clin Lab Sci.* (2015) 52:86-105. doi: 10.3109/10408363.2014.992064. PubMed PMID: 25535770.

13. Lippi G, Cervellin G, Sanchis-Gomar F. Red blood cell distribution width and cardiovascular disorders. Does it really matter which comes first, the chicken or the egg? *Int J Cardiol.* (2016) 206:129-30. doi:10.1016/j.ijcard.2016.01.122. PubMed PMID: 26788688.
14. Yao D, Wang Z, Cai H, Li Y, Li B. Relationship between red cell distribution width and prognosis in patients with breast cancer after operation: a retrospective cohort study. *Biosci Rep.* (2019) 39:BSR20190740. doi:10.1042 /BSR20190740. PubMed PMID: 31262969; PubMed Central PMCID: PMC6629944.
15. Podhorecka M, Halicka D, Szymczyk A, Macheta A, Chocholska S, Hus M, et al. Assessment of red blood cell distribution width as a prognostic marker in chronic lymphocytic leukemia. *Oncotarget.* (2016) 7:32846-53. doi:10.18632/oncotarget.9055. PubMed PMID: 27147570; PubMed Central PMCID: PMC5078056.
16. Li Z, Hong N, Robertson M, Wang C, Jiang G. Preoperative red cell distribution width and neutrophil-to-lymphocyte ratio predict survival in patients with epithelial ovarian cancer. *Sci Rep.* (2017) 7:43001. doi:10.1038/srep43001. PubMed PMID: 28223716; PubMed Central PMCID: PMC5320446.

17. Kemal Y, Demirag G, Baş B, Önem S, Teker F, Yücel İ. The value of red blood cell distribution width in endometrial cancer. *Clin Chem Lab Med.* (2015) 53:823-7. doi:10.1515/cclm-2014-0699. PubMed PMID: 25860865.
18. Zheng J, X Yuan, W Guo. Relationship between red cell distribution width and prognosis of patients with osteosarcoma. *Biosci Rep.* (2019) 39:BSR20192590. doi:10.1042/BSR20192590. PubMed PMID: 31815279; PubMed Central PMCID: PMC6923327.
19. Oikawa M, Yoshihisa A, Yokokawa T, Misaka T, Yaegashi D, Miyata M, et al. Cardiac Troponin I Predicts Elevated B-type Natriuretic Peptide in Patients Treated with Anthracycline-Containing Chemotherapy. *Oncology.* (2020) 98:653-660. doi:10.1159/000507585. PubMed PMID: 32454480.
20. Blanter JB, Frishman WH. The Preventive Role of Angiotensin Converting Enzyme Inhibitors/Angiotensin-II Receptor Blockers and  $\beta$ -Adrenergic Blockers in Anthracycline- and Trastuzumab-Induced Cardiotoxicity. *Cardiol Rev.* (2019) 27:256-259. doi:10.1097/crd.0000000000000252. PubMed PMID: 31008768.
21. Chin BS, Langford NJ, Nuttall SL, Gibbs CR, Blann AD, Lip GY. Anti-oxidative properties of beta-blockers and angiotensin-converting enzyme inhibitors in congestive heart failure. *Eur J Heart Fail.* (2003) 5:171-4. doi:10.1016/s1388-9842(02)00251-9. PubMed PMID: 12644008.



22. Berliner D, Beutel G, Bauersachs J. Echocardiography and biomarkers for the diagnosis of cardiotoxicity. *Herz*. (2020) 45: 637-644. doi:10.1007/s00059-020-04957-5. PubMed PMID: 32564096.

## **Figure legends**

### **Figure 1.**

Patient cohort selection.

RDW, red blood cell distribution width.

### **Figure 2.**

Time-dependent changes in EF after anthracycline treatment.

(A) Changes in EF in low RDW group. (B) Changes in EF in high RDW group.

EF, ejection fraction; RDW, red blood cell distribution width.

### **Figure 3.**

Receiver operator characteristic curve analysis of red blood cell distribution width predicting the occurrence of cancer therapeutics-related myocardial disorder by anthracycline.

AUC, area under the curve.

**Table 1. Baseline clinical characteristics of patients with high or low RDW**

	Low RDW (n=98)	High RDW (n=104)	P value
Age, years	58.0 (47.5-66.0)	54.0 (45.0-65.0)	0.396
Female, n (%)	81 (82.6)	81 (77.8)	0.395
Body mass index, kg/m <sup>2</sup>	22.9 ± 3.7	23.7 ± 4.5	0.161
<b>Cardiovascular risk factor</b>			
Hypertension, n (%)	21 (21.4)	26 (25.0)	0.426
Dyslipidemia, n (%)	34 (34.6)	23 (22.1)	0.101
Diabetes mellitus, n (%)	10 (10.2)	12 (11.5)	0.669
Current or past smokers, n (%)	33 (33.6)	36 (34.6)	0.849
Family history of CAD, n (%)	9 (9.1)	14 (13.4)	0.270
CKD (eGFR<60 ml/min/1.73m <sup>2</sup> ), n (%)	15 (15.3)	15 (14.4)	0.858
<b>Pre-treatment cardiovascular medications</b>			
Aspirin, n (%)	2 (2.0)	3 (2.8)	0.528
Statin, n (%)	9 (9.1)	10 (9.6)	0.916
β-blocker, n (%)	1 (1.0)	2 (1.9)	0.522
ACE inhibitor and/or ARB, n (%)	18 (18.3)	12 (11.5)	0.173
<b>Anti-cancer treatment</b>			
Cumulative anthracycline dose, mg/m <sup>2</sup>	200 (180-240)	180 (150-250)	0.203
HER2 inhibitor, n (%)	15 (15.3)	10 (9.6)	0.220
Radiation therapy, n (%)	7 (7.1)	6 (5.7)	0.774
<b>Oncological disease</b>			
Breast cancer, n (%)	59 (60.2)	45 (43.2)	0.016
Hematological tumor, n (%)	20 (20.4)	33 (31.7)	0.068
Gynecologic tumor, n (%)	10 (10.2)	14 (13.4)	0.475
Osteosarcoma, n (%)	8 (8.1)	9 (8.6)	0.900
Other solid tumor, n (%)	1 (1.0)	3 (2.8)	0.333
<b>Laboratory data</b>			
BNP, pg/ml	11.2 (6.6-19.8)	12.4 (5.9-22.7)	0.665
Troponin I, ng/ml	0.017 (0.017-0.017)	0.017 (0.017-0.017)	0.776
Total protein, g/dl	7.10 (6.8-7.5)	7.0 (6.7-7.4)	0.187
Albumin, g/dl	4.2 (3.9-4.5)	4.0 (3.8-4.3)	0.003
AST, U/L	18 (15-21)	19 (15-24)	0.788

ALT, U/L	15 (12-21)	14 (10-25)	0.560
LDH, U/L	181 (153-215)	197 (165-244)	0.060
BUN, mg/dl	13.0 (10.7-15.0)	13.0 (10.0-15.0)	0.509
Creatinine, mg/dl	0.65 (0.57-0.76)	0.66 (0.57-0.78)	0.588
eGFR, ml/min/1.73m <sup>2</sup>	77.0 (63.7-89.2)	72.0 (65.0-89.0)	0.705
Total cholesterol, mg/dl	201.9 ± 36.9	191.5 ± 42.6	0.099
Triglyceride, mg/dl	106 (68.2-166.7)	107.5 (79.7-227.5)	0.979
High density lipoprotein cholesterol, mg/dl	54.9 ± 15.0	53.1 ± 15.5	0.458
Low density lipoprotein cholesterol, mg/dl	120.7 ± 30.9	113.2 ± 36.4	0.157
Hemoglobin A1c, %	5.6 (5.4-5.8)	5.7 (5.5-6.1)	0.185
C-reactive protein, mg/dl	0.11 (0.04-0.38)	0.16 (0.07-0.70)	0.024
Uric acid, mg/dl	4.3 (3.4-5.3)	4.7 (3.6-5.3)	0.876
D dimer, µg/ml	0.5 (0.5-0.925)	0.9 (0.5-2.3)	<0.001
White blood cell, /µl	5550 (4450-6800)	5500 (4200-7200)	0.958
Hemoglobin, g/dl	13.1 (12.4-13.8)	11.8 (10.5-13.2)	<0.001
MCV, fl	93.0 ± 4.2	89.2 ± 8.9	<0.001
PLT, x10 <sup>3</sup> /µl	252.5 ± 72.8	246.6 ± 96.1	0.624
RDW	13.0 (12.6-13.2)	14.9 (13.9-17.0)	<0.001
<b>Echocardiographic data</b>			
LVDdI, mm/m <sup>2</sup>	26.6 (24.5-29.2)	26.3 (24.5-28.5)	0.604
LVDsI, mm/m <sup>2</sup>	16.2 ± 2.4	16.4 ± 2.8	0.680
LVMI, g/m <sup>2</sup>	67.8 (58.7-82.1)	71.3 (61.8-84.9)	0.076
LVEDVI, ml/m <sup>2</sup>	47.0 ± 13.6	46.6 ± 18.6	0.844
LVESVI, ml/m <sup>2</sup>	16.1 (13.4-20.9)	16.2 (12.4-20.1)	0.668
EF, %	64.1 ± 4.9	65.1 ± 5.2	0.181
LAVI, ml/m <sup>2</sup>	22.8 (17.1-28.4)	22.9 (17.3-31.5)	0.333
E/A	0.97 (0.75-0.20)	1.01 (0.76-1.19)	0.710
Mitral regurgitation (mild and above) n, (%)	20 (20.2)	17 (16.5)	0.793
Aortic regurgitation (mild and above) n, (%)	7 (7.1)	8 (7.8)	0.850
Aortic stenosis (mild and above) n, (%)	0	2 (1.9)	0.259

TR-PG, mmHg	19.3 (16.2-22.3)	19.0 (15.0-23.0)	0.463
RVD, mm	27.2 ± 6.3	28.7 ± 5.6	0.098

Values are indicated by mean ± SD, median with interquartile range or n (%). Monoclonal antibodies include HER2 inhibitor. Radiation therapy includes only irradiation to the mediastinum. Hematological tumor includes Hodgkin disease, Non-Hodgkin disease, acute myeloid leukemia, acute lymphocytic leukemia, and chronic lymphocytic leukemia. Gynecologic tumor include uterine cancer or sarcoma and ovarian cancer. Other solid tumors include thymoma, soft tissue tumor, teratoma.

ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BNP, B-type natriuretic peptide; CAD, coronary artery disease; CKD, chronic kidney disease; EF, ejection fraction; eGFR, estimated glomerular filtration rate; GLS, global longitudinal strain; HER2, human epidermal growth factor receptor 2; LAVI, left atrial volume index; LV, left ventricular; LVDdI, LV diastolic dimension index; LVDsI, LV systolic dimension index; LVEDVI, LV end-diastolic volume index; LVESVI, LV end-systolic volume index; LVMI, LV mass index; MCV, mean corpuscular volume; RDW, Red blood cell distribution width; RVD, right ventricular dimension; TR-PG, tricuspid pressure gradient.


**Table2. Parameters associated with the occurrence of CTRCD**

	Univariable		Multivariable*	
	Odds Ratio (95% CI)	P value	Odds Ratio (95% CI)	P value
Age, per 1-year increase	0.986 (0.950-1.023)	0.455		
Female	0.898 (0.239-0.384)	0.874		
Hypertension	0.511 (0.110-2.371)	0.391	0.264 (0.03-1.78)	0.171
Dyslipidemia	0.186 (0.024-1.446)	0.110		
Diabetes mellitus	0.586 (0.073-4.711)	0.615		
Current or past smoker	0.299 (0.065-1.374)	0.121		
Cumulative anthracycline dose, mg/m <sup>2</sup> per 1.0 increase	1.010 (1.004-1.016)	0.001	1.010 (1.00-1.02)	<0.001
HER2 inhibitor	0.526 (0.066-4.201)	0.544		
Radiation therapy	1.077 (0.130-8.941)	0.945		
BNP, pg/ml per 1.0 increase	1.000 (0.976-1.025)	0.998		
Albumin, per 1.0 increase	0.469 (0.171-1.286)	0.141	0.367 (0.09-1.35)	0.131
LVMI, g/m <sup>2</sup> per 1.0 increase	0.998 (0.970-1.027)	0.876		
LVEDVI, ml/m <sup>2</sup> per 1.0 increase	0.994 (0.959-1.024)	0.574		
LVESVI, ml/m <sup>2</sup> per 1.0 increase	1.072 (0.970-1.178)	0.149		
EF, per 1.0 increase	0.926 (0.826-1.038)	0.186	0.868 (0.75-1.01)	0.058
LAVI, ml/m <sup>2</sup> per 1.0 increase	0.999 (0.967-1.031)	0.824		
RDW, per 1.0 increase	1.378 (1.126-1.687)	0.002	1.390 (1.09-1.78)	0.008

\*Adjusted for hypertension, cumulative anthracycline dose, albumin, ejection fraction, and RDW categorical variables.

BNP, B-type natriuretic peptide; CI, Confidence interval; CTRCD, cancer therapeutics-related myocardial disorder; EF, ejection fraction; HER2, human epidermal growth factor receptor 2; LAVI, left atrial volume index; LVEDVI, left ventricular end-diastolic volume index; LVESVI, left ventricular end-systolic volume index; LVMI, left ventricular mass index; RDW, red blood cell distribution width.

**Figure 1.**




Patient cohort selection.

RDW, red blood cell distribution width.




Figure 2.



Time-dependent changes in EF after anthracycline treatment.  
(A) Changes in EF in low RDW group. (B) Changes in EF in high RDW group.  
EF, ejection fraction; RDW, red blood cell distribution width.

**Figure 3.**



Receiver operator characteristic curve analysis of red blood cell distribution width predicting the occurrence of cancer therapeutics-related myocardial disorder by anthracycline.

AUC, area under the curve.